Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national
designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of
trastuzumab, and within the SC by the administration through the vial or device
self-administration in patients with disseminated breast cancer HER2.